ANDOVER, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that, in response to challenges associated with raising additional capital and pursuing strategic alternatives to secure additional funding, including current market conditions, the Company's board of directors has approved a workforce reduction of approximately 55 employees, representing substantially all of Oncorus' workforce, which is expected to be completed by August 2023. Theodore (Ted) Ashburn, M.D., Ph.D. (Chief Executive Officer), Stephen W. Harbin (C

IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

Research collaboration leverages Oncorus' proprietary ionizable amines, PEG lipids, LNP formulations, process development and manufacturing together with Daewoong's mRNA expertiseOpportunity for future license, manufacturing and supply agreement for formulated drug candidates ANDOVER, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, and Daewoong Pharmaceutical Co., Ltd. (KRX: 069620), a leading South Korean pharmaceutical company, today announced a research collaboration for the discovery and development of novel lipid nanoparticle

Maxim Group initiated coverage of Oncorus with a rating of Buy and set a new price target of $35.00

3 - Oncorus, Inc. (0001671818) (Issuer)

3 - Oncorus, Inc. (0001671818) (Issuer)

4 - Oncorus, Inc. (0001671818) (Issuer)

DEFA14A - Oncorus, Inc. (0001671818) (Filer)

15-12G - Oncorus, Inc. (0001671818) (Filer)

DEFA14A - Oncorus, Inc. (0001671818) (Filer)

IND submission for ONCR-021 still planned for mid-2023, subject to receipt of additional funding Ended the quarter with $45.0 million in cash, cash equivalents and investments ANDOVER, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing intravenously administered, self-amplifying RNA to transform outcomes for cancer patients, today reported first quarter financial results and provided an update on its business. "Oncorus is pioneering a first-of-its-kind, self-amplifying RNA platform with an exciting lead program, ONCR-021, with plans to submit an IND with the FDA in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., Pres

-Former CEO of Dicerna brings deep expertise in RNA research, drug development, business development and financing- CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Douglas M. Fambrough, III, Ph.D. to its board of directors. "We are thrilled to welcome Doug to our board and leverage his significant expertise and executive leadership skills as we work to advance our next-generation HSV and selectively self-amplifying vRNA/LNP platforms," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer

CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), a viral immunotherapy company focused on driving innovation to transform outcomes for cancer patients, today announced the appointment of Richard Wanstall as Chief Financial Officer. "We are pleased to welcome Rick as our Chief Financial Officer and we look forward to drawing from his notable experience leading biotech companies through significant organizational growth," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus. "Rick is a trusted colleague that I, as well as other members of the senior leadership team, have had the pleasure of working alongside in our previ

Company now focused on the development of ONCR-021, Oncorus' lead self-amplifying RNA product candidate for non-small cell lung and other cancers; program remains on track for IND submission in mid-2023Phase 1 clinical trial of ONCR-177 in patients with advanced disease is being discontinuedPrioritization of ONCR-021 and reduction in workforce reduces company's cash burn rate; Oncorus reiterates guidance of cash runway into early 2024 ANDOVER, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ:ONCR), an RNA medicines company focused on developing IV administered, self-amplifying RNA to transform outcomes for cancer patients, today announced that it is reprioritizing its pipeli

Data presented from ongoing Phase 1 clinical trial of ONCR-177 in multiple solid tumor indications at RP2D at SITC 2021 and preclinical studies of ONCR-GBM targeting brain cancer at IOVC 2021Signed exclusive licensing agreement with Gaeta Therapeutics for use of locally delivered IL-12 via oncolytic viral expression in combination with immune checkpoint inhibitorsAdditional clinical data from ONCR-177 surface lesion monotherapy expansion and combination expansion cohorts expected in second half of 2022Continued to advance preclinical programs, including ONCR-021 towards IND filing in mid-2023Strengthened executive leadership team with promotion of John Goldberg, M.D., to Chief Medical Office

ONCR-177 was well tolerated with no dose-limiting toxicities in the surface lesion dose escalation part of the first-in-human study in heavily pretreated patients with advanced, injectable solid tumorsRecommended Phase 2 dose (RP2D) selected and expansion monotherapy cohort dosing is underwayThree of eight evaluable patients at RP2D across multiple indications (cutaneous melanoma, head and neck cancer, and mucosal melanoma) experienced clinical benefit after two doses of single-agent ONCR-177Proof of principle established for propriety Herpes Simplex Virus (HSV) platform that leverages microRNA attenuation to enable interferon resistance via retention of γ34.5 and five complementary immunomo

SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

SC 13G/A - Oncorus, Inc. (0001671818) (Subject)

SC 13G/A - Oncorus, Inc. (0001671818) (Subject)